Past and current perspective on new therapeutic targets for Type-II diabetes
| Autor: | Umesh B Mahajan, Chandragouda R. Patil, Yogeeta O. Agrawal, Sandip S Chaudhari, Shreesh Ojha, Sameer N. Goyal, Pradip D Patil, Kalpesh R. Patil |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Blood Glucose
0301 basic medicine Combination therapy United Kingdom Prospective Diabetes Study medicine.medical_treatment Pharmaceutical Science Review Disease therapeutic targets Bioinformatics 03 medical and health sciences Therapeutic approach Insulin resistance insulin resistance Diabetes mellitus Drug Discovery Animals Humans Hypoglycemic Agents Medicine Molecular Targeted Therapy Pharmacology business.industry Insulin medicine.disease Treatment Outcome 030104 developmental biology Diabetes Mellitus Type 2 Drug development Type-II diabetes mellitus Drug Therapy Combination business Biomarkers Signal Transduction discontinued drugs |
| Zdroj: | Drug Design, Development and Therapy |
| ISSN: | 1177-8881 |
| DOI: | 10.2147/dddt.s133453 |
| Popis: | Loss of pancreatic β-cell function is a hallmark of Type-II diabetes mellitus (DM). It is a chronic metabolic disorder that results from defects in both insulin secretion and insulin action. Recently, United Kingdom Prospective Diabetes Study reported that Type-II DM is a progressive disorder. Although, DM can be treated initially by monotherapy with oral agent; eventually, it may require multiple drugs. Additionally, insulin therapy is needed in many patients to achieve glycemic control. Pharmacological approaches are unsatisfactory in improving the consequences of insulin resistance. Single therapeutic approach in the treatment of Type-II DM is unsuccessful and usually a combination therapy is adopted. Increased understanding of biochemical, cellular and pathological alterations in Type-II DM has provided new insight in the management of Type-II DM. Knowledge of underlying mechanisms of Type-II DM development is essential for the exploration of novel therapeutic targets. Present review provides an insight into therapeutic targets of Type-II DM and their role in the development of insulin resistance. An overview of important signaling pathways and mechanisms in Type-II DM is provided for the better understanding of disease pathology. This review includes case studies of drugs that are withdrawn from the market. The experience gathered from previous studies and knowledge of Type-II DM pathways can guide the anti-diabetic drug development toward the discovery of clinically viable drugs that are useful in Type-II DM. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|